CareMax, Inc. (CMAX)
NASDAQ: CMAX · IEX Real-Time Price · USD
4.910
+0.510 (11.59%)
Mar 28, 2024, 12:34 PM EDT - Market open
CareMax Stock Forecast
CMAX's stock price has decreased by -93.31% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for CareMax stock have an average target of 45, with a low estimate of 30 and a high estimate of 60. The average target predicts an increase of 816.50% from the current stock price of 4.91.
Analyst Consensus: Hold
* Price targets were last updated on Nov 17, 2023.
Analyst Ratings
The average analyst rating for CareMax stock from 2 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 2 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
UBS | UBS | Strong Buy → Hold Downgrades $150 → $30 | Strong Buy → Hold | Downgrades | $150 → $30 | +511.00% | Nov 17, 2023 |
Piper Sandler | Piper Sandler | Buy → Hold Downgrades $60 | Buy → Hold | Downgrades | $60 | +1,122.00% | Nov 10, 2023 |
UBS | UBS | Strong Buy Maintains $300 → $180 | Strong Buy | Maintains | $300 → $180 | +3,565.99% | Jan 6, 2023 |
Truist Securities | Truist Securities | Hold Initiates $225 | Hold | Initiates | $225 | +4,482.48% | Sep 7, 2022 |
Jefferies | Jefferies | Strong Buy Initiates $450 | Strong Buy | Initiates | $450 | +9,064.97% | Oct 20, 2021 |
Financial Forecast
Revenue This Year
891.15M
from 751.10M
Increased by 18.65%
Revenue Next Year
1.69B
from 891.15M
Increased by 89.53%
EPS This Year
-15.03
from -183.31
EPS Next Year
-3.43
from -15.03
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 1.0B | 2.4B | 4.0B | 4.5B | 5.0B |
Avg | 891.2M | 1.7B | 3.0B | 4.3B | 4.9B |
Low | 809.1M | 1.1B | 2.1B | 4.2B | 4.7B |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 35.0% | 170.2% | 135.1% | 49.3% | 15.8% |
Avg | 18.6% | 89.5% | 77.4% | 45.0% | 12.4% |
Low | 7.7% | 21.8% | 21.6% | 39.3% | 8.0% |
EPS Forecast
EPS | 2024 | 2025 |
---|---|---|
High | -6.30 | 7.88 |
Avg | -15.03 | -3.43 |
Low | -28.95 | -14.58 |
EPS Growth
EPS Growth | 2024 | 2025 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.